Subasumstat (TAK-981) is a first-in-class and selective inhibitor of the SUMOylation enzymatic cascade, demonstrating potential immune-activating and antineoplastic activities. It increases the production of type 1 IFN, enhancing type 1 IFN-mediated signaling, activating innate effector cells, and improving antitumor innate immune responses. A single subcutaneous injection induces activation of dendritic cells.
- First-in-class selective inhibitor of SUMOylation enzymatic cascade
- Potential immune-activating activities
- Potential antineoplastic activities
- Increases production of type 1 IFN
- Enhances antitumor innate immune responses
- Activates innate effector cells
- Induces activation of dendritic cells